Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Italian Stock Exchange  >  Luxottica Group SpA    LUX   IT0001479374

End-of-day quote. End-of-day quote  - 06/24
45.3 EUR   -3.33%
06/21 LUXOTTICA : Report on the purchase of treasury shares under buyback ..
06/16 LUXOTTICA : By Laws May 31, 2016
06/14 LUXOTTICA : Report on the purchase of treasury shares under buyback ..
Analysis summary4-Traders Strategies 

Luxottica Group SpA : In horizontal mouvement

share with twitter share with LinkedIn share with facebook
share via e-mail
04/19/2012 | 02:28pm
Opinion : En surveillance. Surveiller le range EUR 25.9/ EUR 27.5
Other Specialty Retailers

Luxottica is luxury Italian brand specialized in design, manufacture, distribute of eyeglass frames and sunglasses. Products are sold under its own brands as Ray ban, Oakley and Persol and under licenses, especially Giorgio Armani, Chanel and Moschino. The share is listed both on Milan stock exchange and New York stock exchange.

The full year report 2011 showed interesting numbers. In fact company’s revenues rose more than 7% against one year previous, to $6.2 milliard, with net income up 12% to $452 million. The largest market remains North America with 58% of revenues, and then Europe (20%) and Asia (12.5%). Thomson Reuters’ consensus has recently revised upward the earnings per share estimates for 2012 and 2013 financial years.

The share during 2011 outperformed FTSE MIB 30 (Italian Index composed by the 30 largest companies in the country), underlining the defensive character of luxury sector. The same dynamic is persisted in 2012, when the share gained more than 20% while the Italian index remains almost stable. Since February the share is trading in neutral range with consolidation horizontal phase. We suggest to give attention the breakout of this range and could lead the share to historical highest near to EUR 30.

Luxottica Group SpA : Luxottica Group SpA : In horizontal mouvement

© Zonebourse.com 2012

share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: 4-traders.com is a website published by SURPERFORMANCE SAS. Surperformance or 4-traders.com is not a registered broker-dealer nor a registered investment adviser. You understand that this web site and its content is furnished for your personal, noncommercial, informational purposes only, and that no mention of a particular security in this website constitutes a recommendation to buy, sell, or hold any other security, nor that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. Surperformance and 4-traders.com services will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. Information regarding trading and investment as provided by Surperformance professional is not tailored to the investment needs of any specific person. You acknowledge that you are responsible for your own financial decisions and should seek a registered financial agent depending on your own risk tolerance to advise you on your personal trading activities.

Financial Ratios

Size 2016e 2017e
Capitalization 21 917 M€ -
Entreprise Value (EV) 22 594 M€ 22 120 M€
Valuation 2016e 2017e
P/E ratio (Price / EPS) 24,0x 21,5x
Capitalization / Revenue 2,34x 2,21x
EV / Revenue 2,42x 2,23x
EV / EBITDA 11,2x 10,1x
Yield (DPS / Price) 2,12% 2,16%
Price to book (Price / BVPS) 3,90x 3,57x
Profitability 2016e 2017e
Operating Margin (EBIT / Sales) 16,2% 16,8%
operating Leverage (Delta EBIT / Delta Sales) 0,88x 1,64x
Net Margin (Net Profit / Revenue) 9,69% 10,2%
ROA (Net Profit / Asset) 10,2% 10,8%
ROE (Net Profit / Equities) 16,3% 16,7%
Rate of Dividend 51,0% 46,4%
Balance Sheet Analysis 2016e 2017e
CAPEX / Sales   5,98% 5,79%
Cash Flow / Sales 15,0% 15,3%
Capital Intensity (Assets / Sales) 0,95x 0,94x
Financial Leverage (Net Debt / EBITDA) 0,34x 0,09x
Income Statement Evolution
More Financials
EPS Revisions